Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346


Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.

de Velde F, de Winter BCM, Neely MN, Yamada WM, Koch BCP, Harbarth S, von Dach E, van Gelder T, Huttner A, Mouton JW; COMBACTE-NET consortium.

Clin Pharmacokinet. 2020 Jan 20. doi: 10.1007/s40262-020-00859-1. [Epub ahead of print]


Correction to: Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Nonobese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2020 Jan 9;37(2):32. doi: 10.1007/s11095-020-2756-7.


Oral fosfomycin efficacy with variable urinary exposures following single and multiple doses against Enterobacterales: the importance of heteroresistance on growth outcome.

Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY.

Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01982-19. doi: 10.1128/AAC.01982-19. [Epub ahead of print]


Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.

Abbott IJ, Dekker J, van Gorp E, Wijma RA, Raaphorst MN, Klaassen CHW, Meletiadis J, Mouton JW, Peleg AY.

J Antimicrob Chemother. 2019 Dec 24. pii: dkz519. doi: 10.1093/jac/dkz519. [Epub ahead of print]


Diagnostic and medical needs for therapeutic drug monitoring of antibiotics.

Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris J, Roberts JA, Cotta MO, van Belkum A, Caniaux I.

Eur J Clin Microbiol Infect Dis. 2019 Dec 11. doi: 10.1007/s10096-019-03769-8. [Epub ahead of print] Review.


Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage.

Huttner A, Bielicki J, Clements MN, Frimodt-Møller N, Muller AE, Paccaud JP, Mouton JW.

Clin Microbiol Infect. 2019 Dec 4. pii: S1198-743X(19)30630-5. doi: 10.1016/j.cmi.2019.11.028. [Epub ahead of print] Review.


Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.

Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA study group.

Clin Infect Dis. 2019 Nov 23. pii: ciz1146. doi: 10.1093/cid/ciz1146. [Epub ahead of print]


Zinc-Impregnated Mesh for Abdominal Wall Repair Reduces Infection in a Rat Model of Peritonitis.

Yurtkap Y, Jairam AP, Kaufmann R, Kroese LF, Clahsen-van Groningen MC, Mouton JW, Menon AG, Kleinrensink GJ, Jeekel J, Lange JF, Belt EJ.

J Surg Res. 2020 Feb;246:560-567. doi: 10.1016/j.jss.2019.09.046. Epub 2019 Oct 24.


Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model.

Beredaki MI, Georgiou PC, Siopi M, Kanioura L, Arendrup MC, Mouton JW, Meletiadis J.

J Antimicrob Chemother. 2020 Jan 1;75(1):140-148. doi: 10.1093/jac/dkz425.


Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals.

Smit C, Wasmann RE, Goulooze SC, Wiezer MJ, van Dongen EPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Br J Clin Pharmacol. 2019 Oct 29. doi: 10.1111/bcp.14144. [Epub ahead of print]


Cefpirome Treatment Results in Limited Selection of Stable Derepressed Enterobacter cloacae Mutants in the Intestinal Flora of Rats Treated for an Experimental Klebsiella pneumoniae Pulmonary Infection.

Gautam V, Mouton JW, Ten Kate MT, Bakker-Woudenberg IAJM, van Burgh S, Strepis N, Klaassen CHW, Goessens W.

Microb Drug Resist. 2019 Oct 29. doi: 10.1089/mdr.2018.0473. [Epub ahead of print]


Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers.

Wijma RA, Huttner A, van Dun S, Kloezen W, Abbott IJ, Muller AE, Koch BCP, Mouton JW.

Int J Antimicrob Agents. 2019 Oct;54(4):435-441. doi: 10.1016/j.ijantimicag.2019.07.018. Epub 2019 Aug 2.


Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.

Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF.

J Fungi (Basel). 2019 Jul 1;5(3). pii: E55. doi: 10.3390/jof5030055. Review.


Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.

Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM.

J Antimicrob Chemother. 2019 Oct 1;74(10):2930-2933. doi: 10.1093/jac/dkz267.


Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine.

Wijma RA, Hoogtanders KEJ, Croes S, Mouton JW, Brüggemann RJM.

J Pharm Biomed Anal. 2019 Sep 10;174:161-167. doi: 10.1016/j.jpba.2019.05.054. Epub 2019 May 28.


Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2019 May 30;36(8):112. doi: 10.1007/s11095-019-2651-2. Erratum in: Pharm Res. 2020 Jan 9;37(2):32.


Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Meletiadis J, Siopi M, Kanioura L, Jørgensen KM, Perlin DS, Mouton JW, Arendrup MC.

J Antimicrob Chemother. 2019 Aug 1;74(8):2247-2254. doi: 10.1093/jac/dkz154.


A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.

Smit C, Wasmann RE, Goulooze SC, Hazebroek EJ, Van Dongen EPA, Burgers DMT, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Clin Pharmacokinet. 2019 Oct;58(10):1333-1343. doi: 10.1007/s40262-019-00762-4.


Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authors' response.

Mouton JW, Meletiadis J, Voss A, Turnidge J.

J Antimicrob Chemother. 2019 Jun 1;74(6):1761-1762. doi: 10.1093/jac/dkz142. No abstract available.


In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Siopi M, Mouton JW, Pournaras S, Meletiadis J.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02673-18. doi: 10.1128/AAC.02673-18. Print 2019 Jun.


Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?

Wijma RA, Fransen F, Muller AE, Mouton JW.

Drug Resist Updat. 2019 Mar;43:1-9. doi: 10.1016/j.drup.2019.03.001. Epub 2019 Mar 20. Review.


The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study.

Huttner A, Wijma RA, Stewardson AJ, Olearo F, Von Dach E, Harbarth S, Brüggemann RJM, Mouton JW, Muller AE.

J Antimicrob Chemother. 2019 Jun 1;74(6):1656-1661. doi: 10.1093/jac/dkz095.


Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.

Melchers MJ, Teague J, Warn P, Hansen J, Bernardini F, Wach A, Obrecht D, Dale GE, Mouton JW.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01699-18. doi: 10.1128/AAC.01699-18. Print 2019 Mar.


Erratum for Meletiadis et al., "Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone".

Meletiadis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02184-18. doi: 10.1128/AAC.02184-18. Print 2018 Dec. No abstract available.


Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group .

Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.


High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers - authors' response.

Wijma RA, Koch BCP, van Gelder T, Mouton JW.

Clin Microbiol Infect. 2019 Feb;25(2):256-257. doi: 10.1016/j.cmi.2018.10.017. Epub 2018 Nov 9. No abstract available.


Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.

Tsala M, Vourli S, Georgiou PC, Pournaras S, Daikos GRL, Mouton JW, Meletiadis J.

J Antimicrob Chemother. 2019 Feb 1;74(2):387-394. doi: 10.1093/jac/dky422.


Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility.

Lellouche J, Schwartz D, Elmalech N, Ben Dalak MA, Temkin E, Paul M, Geffen Y, Yahav D, Eliakim-Raz N, Durante-Mangoni E, Iossa D, Bernardo M, Daikos GL, Skiada A, Pantazatou A, Antoniadou A, Mouton JW, Carmeli Y; AIDA study group.

Clin Microbiol Infect. 2019 Jun;25(6):711-716. doi: 10.1016/j.cmi.2018.09.014. Epub 2018 Oct 4.


How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates.

Guinea J, Verweij PE, Meletiadis J, Mouton JW, Barchiesi F, Arendrup MC; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).

Clin Microbiol Infect. 2019 Jun;25(6):681-687. doi: 10.1016/j.cmi.2018.09.008. Epub 2018 Sep 28. Review.


An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics.

Otto RG, van Gorp E, Kloezen W, Meletiadis J, van den Berg S, Mouton JW.

Int J Antimicrob Agents. 2019 Jan;53(1):34-39. doi: 10.1016/j.ijantimicag.2018.09.003. Epub 2018 Sep 19.


Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates.

Mouton JW.

Eur J Pharm Sci. 2018 Dec 1;125:23-27. doi: 10.1016/j.ejps.2018.09.008. Epub 2018 Sep 12.


Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline.

Wijma RA, Huttner A, Koch BCP, Mouton JW, Muller AE.

J Antimicrob Chemother. 2018 Nov 1;73(11):2916-2926. doi: 10.1093/jac/dky255. Review.


Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision.

Mouton JW, Meletiadis J, Voss A, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2374-2379. doi: 10.1093/jac/dky232.


MIC-based dose adjustment: facts and fables-authors' response.

Mouton JW, Muller AE, Canton R, G Giske C, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2585-2586. doi: 10.1093/jac/dky195. No abstract available.


Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, Harbarth S; COMBACTE-NET Consortium.

Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.


Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.

de Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP.

Pharmacol Res. 2018 Aug;134:280-288. doi: 10.1016/j.phrs.2018.07.005. Epub 2018 Jul 6. Review.


The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.


Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study.

Gautam V, Shafiq N, Mouton JW, Malhotra S, Kaur S, Ray P.

Indian J Med Res. 2018 Apr;147(4):407-412. doi: 10.4103/ijmr.IJMR_1464_16.


Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion.

van den Bijllaardt W, Schijffelen MJ, Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, Le TN, Overdevest I, Stals F, Voorn P, Waar K, Mouton JW, Muller AE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2380-2387. doi: 10.1093/jac/dky214.


Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement.

van Mens SP, Ten Doesschate T, Kluytmans-van den Bergh MFQ, Mouton JW, Rossen JWA, Verhulst C, Bonten MJM, Kluytmans JAJW.

Int J Antimicrob Agents. 2018 Nov;52(5):678-681. doi: 10.1016/j.ijantimicag.2018.06.014. Epub 2018 Jun 27.


Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.

Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J.

J Antimicrob Chemother. 2018 Aug 1;73(8):2274. doi: 10.1093/jac/dky218. No abstract available.


Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.

Muller AE, Punt N, Engelhardt M, Schmitt-Hoffmann AH, Mouton JW.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):781-787. doi: 10.1002/cpdd.465. Epub 2018 May 16.


Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial.

van den Boom AL, de Wijkerslooth EML, van Rosmalen J, Beverdam FH, Boerma EG, Boermeester MA, Bosmans JWAM, Burghgraef TA, Consten ECJ, Dawson I, Dekker JWT, Emous M, van Geloven AAW, Go PMNYH, Heijnen LA, Huisman SA, Jean Pierre D, de Jonge J, Kloeze JH, Koopmanschap MA, Langeveld HR, Luyer MDP, Melles DC, Mouton JW, van der Ploeg APT, Poelmann FB, Ponten JEH, van Rossem CC, Schreurs WH, Shapiro J, Steenvoorde P, Toorenvliet BR, Verhelst J, Versteegh HP, Wijnen RMH, Wijnhoven BPL.

Trials. 2018 May 2;19(1):263. doi: 10.1186/s13063-018-2629-0.


Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S.

JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.


Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.


Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Arendrup MC, Meletiadis J, Zaragoza O, Jørgensen KM, Marcos-Zambrano LJ, Kanioura L, Cuenca-Estrella M, Mouton JW, Guinea J.

Clin Microbiol Infect. 2018 Nov;24(11):1200-1204. doi: 10.1016/j.cmi.2018.02.021. Epub 2018 Mar 2.


A New Marker of Echinocandin Activity in an In Vitro Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection.

Meletiadis J, Siopi M, Tsakris A, Mouton JW, Pournaras S.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02322-17. doi: 10.1128/AAC.02322-17. Print 2018 May.


Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.


Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.

Ortiz Zacarías NV, Dijkmans AC, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Kamerling IMC, Stevens J.

Pharmacol Res Perspect. 2018 Feb;6(1). doi: 10.1002/prp2.378.

Supplemental Content

Loading ...
Support Center